APA (7th ed.) Citation

Wu, Y., Zhou, C., Liam, C., Wu, G., Liu, X., Zhong, Z., . . . ., e. a. (2015). First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Oxford University Press on behalf of the European Society for Medical Oncology.

Chicago Style (17th ed.) Citation

Wu, Y-L, et al. First-line Erlotinib Versus Gemcitabine/cisplatin in Patients with Advanced EGFR Mutation-positive Non-small-cell Lung Cancer: Analyses from the Phase III, Randomized, Open-label, ENSURE Study. Oxford University Press on behalf of the European Society for Medical Oncology, 2015.

MLA (8th ed.) Citation

Wu, Y-L, et al. First-line Erlotinib Versus Gemcitabine/cisplatin in Patients with Advanced EGFR Mutation-positive Non-small-cell Lung Cancer: Analyses from the Phase III, Randomized, Open-label, ENSURE Study. Oxford University Press on behalf of the European Society for Medical Oncology, 2015.